- Home
- Applications
- europe
- cancer diagnostic
Show results for
Refine by
Cancer Diagnostic Product Applications In Europe
5 applications found
PLGA nanospheres have already been successfully used in vitro and in clinical trials. Results show that drugs encapsulated in PLGA nanoparticles have superior accumulation in the tumor environment, reduced tumor size and enhanced inhibition of cell proliferation. This is thanks to increased cell penetration and reduced toxicity of encapsulated compounds. Because of the higher accumulation in tumoral areas PLGA nanoparticles are also useful for cancer diagnosis and imaging which has a key role in clinical oncology ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Providing physicians with innovative and meaningful assays for the earlier detection of clinically significantly prostate ...
ByMDxHealth based in Irvine, CALIFORNIA (USA)
Prostate cancer is the fourth most common cancer diagnosis in worldwide, with 1 300 000 new cases and 360 000 deaths in 2018 (Globocan 2018). At the initial diagnosis the disease, more than 60% of cases are diagnosed as localized prostate cancer. Localized prostate cancer can be asymptomatic at the early stage and often has an indolent course that may require only active surveillance. Indolent or aggressive, to treat or not to treat this cancer? This is always the question urologists ask themselves. ...
ByOncoDiag based in Miserey, FRANCE
Tumor markers found in blood, urine and body tissues can be used in diagnosing and treating cancer. Each tumor marker is indicative of a particular disease and thus can be used for the screening, monitoring and diagnosis of specific tumor types. In addition to being used in prognosis, these molecular markers help to predict the response, resistance and toxicity to therapy. For example, BCR-ABL gene sequence detection is used to diagnose chronic myelogenous leukemia and acute lymphatic ...
ByAurora Biomed Inc. based in Vancouver, BRITISH COLUMBIA (CANADA)
Bladder cancer is the seventh most common cancer diagnosis in worldwide, with 500 000 new cases and 200 000 deaths in 2018 (Globocan 2018). More than 2.7 million people have a history of bladder cancer worldwide. At the initial diagnosis of bladder cancer, more than 80% of cases are diagnosed as non-muscle-invasive bladder cancer (NMIBC). Due to the very high recurrence rate (>80%), NMIBC patients require lifelong surveillance with periodic follow-up cystoscopy (an unpleasant invasive exam) and urine cytology ...
ByOncoDiag based in Miserey, FRANCE